Phaseline

Targets › TIGIT

TIGIT (T-cell immunoreceptor with Ig and ITIM domains): drug programs, companies and trials

18 programs from 16 companies in 102 trials: 58 Phase 2, 23 Phase 3, 21 Phase 1; Oncology; next expected readout Nov 2026.

Inhibitory receptor that plays a role in the modulation of immune responses. Suppresses T-cell activation by promoting the generation of mature immunoregulatory dendritic cells. (UniProt, Q495A1)

Open in Phaseline: the race on TIGIT, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
RocheTiragolumab
T-cell immunoreceptor with Ig and ITIM domains inhibitor
TIGITPhase 3Hepatocellular Carcinoma; Cancer; Renal Cell Carcinoma; Rectal Neoplasms …Nov 2026
AstraZenecaVolrustomig (MEDI5752)
CTLA-4/PD-1 bispecific antibody
CTLA4, PDCD1, TIGITPhase 3Metastatic Non-small Cell Lung Cancer; Locally Advanced Cervical Cancer; Unresectable Pleural Mesothelioma; Locally Advanced Head and Neck Squamous Cell Carcinoma …Jan 2027
Gilead SciencesDomvanalimab
T-cell immunoreceptor with Ig and ITIM domains inhibitor
TIGITPhase 3Non-small Cell Lung Cancer; Head and Neck Squamous Cell Carcinoma; Advanced Non-Small Cell Lung Cancer; Lung Cancer …Mar 2027
AstraZenecaAZD2936 (rilvegostomig)
Anti-TIGIT/anti-PD-1 bispecific antibody
TIGIT, PDCD1Phase 3Non-small Cell Lung Cancer; Biliary Tract Cancer; Endometrial Cancer; HER2-positive Gastric Cancer …Mar 2027
Summit TherapeuticsIvonescimab Dose 1
TIGIT inhibitor
TIGIT, CTLA4Phase 3Non-Small Cell Lung Cancer; Metastatic Urothelial CarcinomaApr 2028
Hebei Medical University Fourth HospitalIparomlimab
CTLA-4 inhibitor
CTLA4, TIGITPhase 2Esophageal Squamous Cell Carcinoma (ESCC); AFP Gastric or Gastroesophageal Junction Adenocarcinoma; Colon CancerDec 2026
Qianfoshan HospitalAdebelizumab
TIGIT antagonist monoclonal antibody
TIGITPhase 2Extensive Small Cell Lung CancerDec 2026
M.D. Anderson Cancer CenterEtigilimab
TIGIT inhibitor
TIGITPhase 2Ovarian CancerFeb 2027
Shanghai Henlius BiotechHLX53
Anti-TIGIT Fc fusion protein
TIGITPhase 2Carcinoma, HepatocellularFeb 2027
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityIparomlimab
TIGIT inhibitor
TIGITPhase 2Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma; Head and Neck CancerAug 2027
University of Texas Southwestern Medical CenterLigufalimab (AK117)
TIGIT inhibitor
TIGITPhase 2Advanced Hepatocellular CarcinomaMay 2029
Hebei Medical University Fourth HospitalEnlonstobart
TIGIT antagonist monoclonal antibody
TIGITPhase 2Efficacy and Safety of Short-course Radiotherapy in Total Neoadjuvant Therapy Combined With Enlonstobart for pMMR Locally Advanced Rectal CancerJun 2030
SCRI Development Innovations, LLCatigotatug
TIGIT inhibitor
TIGITPhase 2Limited Stage Small Cell Lung CancerMay 2032
Arcus BiosciencesDomvanalimab
T-cell immunoreceptor with Ig and ITIM domains inhibitor
TIGITPhase 2Gastrointestinal Tract Malignancies; Non Small Cell Lung Cancer–
Xencorvudalimab (XmAb20717)
Bispecific monoclonal antibody targeting CTLA-4 and TIGIT
CTLA4, TIGITPhase 2Ovarian Cancer–
Suzhou Suncadia BiopharmaceuticalsAdebelimab
Anti-TIGIT antibody
TIGITPhase 1Recurrent or Metastatic Cervical CancerJan 2027
D3 Bio (Wuxi)D3L-002
Bispecific antibody targeting TIGIT and PVRIG
TIGIT, PVRIGPhase 1Advanced Solid TumorNov 2027
Shanghai Huaota BiopharmaceuticalHB0036
Anti-PD-L1 and anti-TIGIT bifunctional molecule
CD274, TIGITPhase 1Advanced Solid Tumor–

Conditions

Non-small Cell Lung Cancer (5) Hepatocellular Carcinoma (4) Cancer (4) Endometrial Cancer (4) Non-Small Cell Lung Cancer (4) Gastric Cancer (4) Biliary Tract Cancer (3) Metastatic Colorectal Cancer (2) Metastatic Urothelial Carcinoma (2) Advanced Solid Tumor (2) Melanoma (2) Non Small Cell Lung Cancer (2)

Modalities

mixed (8), antibody (7), small molecule (3)

Companies

AstraZeneca (2) Hebei Medical University Fourth Hospital (2) Roche (1) Summit Therapeutics (1) D3 Bio (Wuxi) (1) Gilead Sciences (1) SCRI Development Innovations, LLC (1) University of Texas Southwestern Medical Center (1) Shanghai Henlius Biotech (1) M.D. Anderson Cancer Center (1) Shanghai Huaota Biopharmaceutical (1) Qianfoshan Hospital (1) Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University (1) Xencor (1) Suzhou Suncadia Biopharmaceuticals (1) Arcus Biosciences (1)

Related targets

CTLA4 (4) PDCD1 (2) PVRIG (1) CD274 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.